Advances in the research and application of neurokinin-1 receptor antagonists. / ç¥ç»æ¿è½1åä½æ®æåçç 究ä¸åºç¨è¿å±.
J Zhejiang Univ Sci B
; 25(2): 91-105, 2024 Feb 15.
Article
en En, Zh
| MEDLINE
| ID: mdl-38303494
ABSTRACT
Recently, the substance P (SP)/neurokinin-1 receptor (NK-1R) system has been found to be involved in various human pathophysiological disorders including the symptoms of coronavirus disease 2019 (COVID-19). Besides, studies in the oncological field have demonstrated an intricate correlation between the upregulation of NK-1R and the activation of SP/NK-1R system with the progression of multiple carcinoma types and poor clinical prognosis. These findings indicate that the modulation of SP/NK-1R system with NK-1R antagonists can be a potential broad-spectrum antitumor strategy. This review updates the latest potential and applications of NK-1R antagonists in the treatment of human diseases and cancers, as well as the underlying mechanisms. Furthermore, the strategies to improve the bioavailability and efficacy of NK-1R antagonist drugs are summarized, such as solid dispersion systems, nanonization, and nanoencapsulation. As a radiopharmaceutical therapeutic, the NK-1R antagonist aprepitant was originally developed as radioligand receptor to target NK-1R-overexpressing tumors. However, combining NK-1R antagonists with other drugs can produce a synergistic effect, thereby enhancing the therapeutic effect, alleviating the symptoms, and improving patients quality of life in several diseases and cancers.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antagonistas del Receptor de Neuroquinina-1
/
Neoplasias
Tipo de estudio:
Prognostic_studies
Aspecto:
Patient_preference
Límite:
Humans
Idioma:
En
/
Zh
Revista:
J Zhejiang Univ Sci B
Asunto de la revista:
BIOLOGIA
/
MEDICINA
Año:
2024
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
China